WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * The viral protease inhibitor ritonavir is known to inhibit clearance of intravenous midazolam. * ALT-2074, a catalytic mimic of glutathione oxidase, inhibits human cytochrome P450 3A (CYP3A) isoforms in vitro. WHAT THIS STUDY ADDS: * Short-term administration of low-dose ritonavir increases area under the plasma concentration curve following oral midazolam by a factor of 28. * Therefore ritonavir is an appropriate positive control inhibitor for clinical drug interaction studies involving CYP3A substrates. * Midazolam clearance is weakly inhibited by ALT-2074, consistent with its in vitro profile. AIMS: We evaluated whether 'boosting' doses of ritonavir can serve as a positive control inhibitor for pharmacokinetic drug-drug interaction studies involving cytochrome P450 3A (CYP3A). The study also determined whether 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an investigational organoselenium compound that acts as a catalytic mimic of glutathione oxidase, inhibits CYP3A metabolism in vivo. METHODS:Thirteen healthy volunteers received single 3-mg oral doses of midazolam on three occasions: in the control condition, during co-treatment with low-dose ritonavir (three oral doses of 100 mg over 24 h), and during co-treatment with ALT-2074 (three oral doses of 80 mg over 24 h). RESULTS:Ritonavir increased mean (+/-SE) total area under the curve (AUC) for midazolam by a factor of 28.4 +/- 4.2 (P < 0.001), and reduced oral clearance to 4.2 +/- 0.5% of control (P < 0.001). In contrast, ALT-2074 increased midazolam AUC by 1.25 +/- 0.11 (P < 0.05), and reduced oral clearance to 88 +/- 8% of control. CONCLUSIONS:Low-dose ritonavir produces extensive CYP3A inhibition exceeding that of ketoconazole (typically 10- to 15-fold midazolam AUC enhancement), and is a suitable positive control index inhibitor for drug-drug interaction studies. ALT-2074 inhibits CYP3A metabolism to a small degree that is of uncertain clinical importance.
RCT Entities:
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * The viral protease inhibitor ritonavir is known to inhibit clearance of intravenous midazolam. * ALT-2074, a catalytic mimic of glutathione oxidase, inhibits humancytochrome P450 3A (CYP3A) isoforms in vitro. WHAT THIS STUDY ADDS: * Short-term administration of low-dose ritonavir increases area under the plasma concentration curve following oral midazolam by a factor of 28. * Therefore ritonavir is an appropriate positive control inhibitor for clinical drug interaction studies involving CYP3A substrates. * Midazolam clearance is weakly inhibited by ALT-2074, consistent with its in vitro profile. AIMS: We evaluated whether 'boosting' doses of ritonavir can serve as a positive control inhibitor for pharmacokinetic drug-drug interaction studies involving cytochrome P450 3A (CYP3A). The study also determined whether 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an investigational organoselenium compound that acts as a catalytic mimic of glutathione oxidase, inhibits CYP3A metabolism in vivo. METHODS: Thirteen healthy volunteers received single 3-mg oral doses of midazolam on three occasions: in the control condition, during co-treatment with low-dose ritonavir (three oral doses of 100 mg over 24 h), and during co-treatment with ALT-2074 (three oral doses of 80 mg over 24 h). RESULTS:Ritonavir increased mean (+/-SE) total area under the curve (AUC) for midazolam by a factor of 28.4 +/- 4.2 (P < 0.001), and reduced oral clearance to 4.2 +/- 0.5% of control (P < 0.001). In contrast, ALT-2074 increased midazolam AUC by 1.25 +/- 0.11 (P < 0.05), and reduced oral clearance to 88 +/- 8% of control. CONCLUSIONS: Low-dose ritonavir produces extensive CYP3A inhibition exceeding that of ketoconazole (typically 10- to 15-fold midazolam AUC enhancement), and is a suitable positive control index inhibitor for drug-drug interaction studies. ALT-2074 inhibits CYP3A metabolism to a small degree that is of uncertain clinical importance.
Authors: D J Greenblatt; L L von Moltke; J S Harmatz; A L Durol; J P Daily; J A Graf; P Mertzanis; J L Hoffman; R I Shader Journal: Clin Pharmacol Ther Date: 2000-04 Impact factor: 6.875
Authors: David J Greenblatt; Lisa L von Moltke; Jerold S Harmatz; Steven M Fogelman; Gengsheng Chen; Jennifer A Graf; Polyxane Mertzanis; Susan Byron; Kerry E Culm; Brian W Granda; Johanna P Daily; Richard I Shader Journal: J Clin Pharmacol Date: 2003-04 Impact factor: 3.126
Authors: Jang-Ik Lee; Diego Chaves-Gnecco; Janet A Amico; Patricia D Kroboth; John W Wilson; Reginald F Frye Journal: Clin Pharmacol Ther Date: 2002-12 Impact factor: 6.875
Authors: Laurie P Volak; Michael J Hanley; Gina Masse; Suwagmani Hazarika; Jerold S Harmatz; Vladimir Badmaev; Muhammed Majeed; David J Greenblatt; Michael H Court Journal: Br J Clin Pharmacol Date: 2013-02 Impact factor: 4.335
Authors: Nicolas Hohmann; Franziska Kocheise; Alexandra Carls; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; Gerd Mikus Journal: Clin Pharmacokinet Date: 2016-12 Impact factor: 6.447
Authors: Brian J Kirby; Ann C Collier; Evan D Kharasch; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat Journal: Drug Metab Dispos Date: 2011-03-15 Impact factor: 3.922
Authors: Stefan Bourgeois; Yves Horsmans; Frederik Nevens; Hans van Vlierberghe; Christophe Moreno; Maria Beumont; Leen Vijgen; Veerle van Eygen; Donghan Luo; Vera Hillewaert; Pieter Van Remoortere; Jolanda van de Logt; Sivi Ouwerkerk-Mahadevan Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191